Patents by Inventor Jon P. Durkin

Jon P. Durkin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for treating cancer using IAP antisense oligomer and chemotherapeutic agent
    Patent number: 8012944
    Abstract: The invention features methods, compositions, and kits for treating a patient having a proliferative disease.
    Type: Grant
    Filed: October 28, 2004
    Date of Patent: September 6, 2011
    Assignee: Pharmascience Inc.
    Inventors: Eric LaCasse, Daniel McManus, Jon P. Durkin
  • Antisense IAP nucleobase oligomers and uses thereof
    Patent number: 7638497
    Abstract: The present invention features nucleobase oligomers that hybridize to IAP polynucleotide, and methods for using them to enhance apoptosis and treat proliferative disorders.
    Type: Grant
    Filed: June 30, 2006
    Date of Patent: December 29, 2009
    Assignee: Aegera Therapeutics, Inc.
    Inventors: Eric LaCasse, Daniel McManus, Jon P. Durkin
  • Antisense IAP nucleobase oligomers and uses thereof
    Patent number: 7091333
    Abstract: The present invention features nucleobase oligomers that hybridize to IAP polynucleotides, and methods for using them to enhance apoptosis and treat proliferative diseases.
    Type: Grant
    Filed: March 27, 2003
    Date of Patent: August 15, 2006
    Assignee: Aegera Therapeutics, Inc.
    Inventors: Eric LaCasse, Daniel McManus, Jon P. Durkin
  • Process for indirect targeted immunocytolysis
    Patent number: 5378815
    Abstract: A process is disclosed for treating cancer by the process of indirect targeted immunocytolysis, which comprises conjugating an immunogenic sensitizing agent to a targeting agent which is capable of binding to aberrant cells, such as cancer cells in a human or animal host. The conjugate is then introduced into the body of an animal or human which has previously been actively immunized against the sensitizing agent or concomitantly treated with the appropriate antibody (passive immunization). Binding of the conjugate to the object cells occurs and is accompanied by the binding of antibodies produced against the sensitizing agent. This results in triggering of a complement cascade and/or an antibody-dependent T-cell-mediated response leading to cell destruction. Also disclosed are the novel targeting agent/sensitizing agent conjugates for use in the process. Agents comprise autocrine differentiation-inhibiting factor/toxoid conjugates.
    Type: Grant
    Filed: February 10, 1992
    Date of Patent: January 3, 1995
    Assignees: National Research Council Canada, Consel National de Recherche Scientifique
    Inventors: Velibor Krsmanovic, Jon P. Durkin, Jagmohan L. Bhasin, Jean-Michel Biquard, Phillip A. Macdonald, James F. Whitfield